Joan Carles

Research interests

Publications

• First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

  Nature Medicine · 2023 · 10.1038/s41591-023-02704-x

• Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)01055-3

• Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

  The Lancet · 2022 · 10.1016/s0140-6736(22)00367-1

• Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

  The Lancet Oncology · 2022 · 10.1016/s1470-2045(21)00660-4

• A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

  Radiology · 2021 · https://doi.org/10.1148/radiol.2021200928

• Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1911206

• Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

  Journal of Clinical Oncology · 2019 · 10.1200/jco.18.02031

• Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria

  Clinical Cancer Research · 2019 · https://doi.org/10.1158/1078-0432.ccr-19-2226

• Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid

  Clinical Cancer Research · 2018 · 10.1158/1078-0432.ccr-17-3800

• Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m 2 ) and the Currently Approved Dose (25 mg/m 2 ) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2016.72.1076

• Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)30173-5

• Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)30297-2

• Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(14)71205-7

• Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

  Nature Communications · 2015 · https://doi.org/10.1038/ncomms9839

• Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)

  European Urology · 2014 · 10.1016/j.eururo.2014.02.056

• Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1405095

• Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)

  Annals of Oncology · 2014 · 10.1093/annonc/mdu437

• Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

  New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1209096

• Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

  Annals of Oncology · 2011 · 10.1093/annonc/mdr023

• Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.20.5534

• Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30Gy in 10 fractions compared with 8Gy in single fraction

  Radiotherapy and Oncology · 2008 · 10.1016/j.radonc.2008.05.018

• Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy

  Annals of Oncology · 2007 · 10.1093/annonc/mdl435

• Risk-Adapted Management for Patients With Clinical Stage I Seminoma: The Second Spanish Germ Cell Cancer Cooperative Group Study

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.01.9810

• Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2004.00.1990

• Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma

  Annals of Oncology · 2003 · 10.1093/annonc/mdg241

• Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine

  Cancer · 2002 · 10.1002/cncr.10762

• Phase I-II Study of Paclitaxel, Cisplatin, and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium

  Journal of Clinical Oncology · 2000 · 10.1200/jco.2000.18.18.3247

Current projects

No projects listed.